Quality-adjusted Outcomes Stratified by Response in Patients With Advanced Non-Small-cell Lung Cancer Receiving First-line nab-Paclitaxel/Carboplatin or Paclitaxel/Carboplatin

These results underscore response as an important surrogate for assessment of long-term treatment outcomes in advanced NSCLC.